II: TechBio Weekly News
Latest Trends: IGC Pharma, InveniAI LLC, Evariste Ltd, Rakovina Therapeutics Inc, Creyon Bio Inc, Stoic Therapeutics and Amplify Partners L.P.
✴️ II: TechBio Weekly News
Latest Trends: IGC Pharma, InveniAI LLC, Evariste Ltd, Rakovina Therapeutics Inc, Creyon Bio Inc, Stoic Therapeutics and Amplify Partners L.P.
“If we don't know what we want we're less likely to get it.”
By Max Tegmark, Life 3.0: Being Human in the Age of Artificial Intelligence
II: TechBio Weekly News
💈 IGC Pharma Inc
IGC Pharma (NYSE American: IGC) (a clinical stage pharmaceutical company developing treatments for Alzheimer's disease) announced its participation in a chat hosted by Ascendiant Capital Markets scheduled for January 23, 2025, at 1:00 pm ET (IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat). CEO Ram Mukunda and CCO Claudia Grimaldi will lead the discussion and the management team will provide updates on several key areas including:
Recent progress in the company's Alzheimer's pipeline
Strategic expansion into metabolic disorders
Integration of AI in drug discovery
Just a week ago (January 8, 2025), GC Pharma announced that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers. To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing technology and digital outreach through social media platforms (IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy).
IGC Pharma is channeling AI’s transformative power to mine the depths of decades-worth of Alzheimer’s research, bringing to light novel insights and pioneering advanced treatments faster than ever (IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials). In particular, IGC Pharma announced on December 6, 2023 an AI collaboration with Los Andes University’s Center for Research and Training in AI (“CINFONIA”). The partnership aims to leverage Generative AI to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients. IGC Pharma and CINFONIA jointly intend to develop and train DL algorithms based on state-of-the- art transformer architectures to predict the temporal progression of approximately 1,500 physiological and psychological variables for each patient enrolled in the IGC-AD1 Phase 2 clinical trial.
💈 InveniAI LLC
On January 13, 2025, InveniAI announced several transformative milestones as part of its continued commitment to revolutionizing the drug development process. More specifically, the company launched a wholly owned subsidiary, AlphaMeld Corporation®, a name that reflects its mission to meld advanced AI, ML and generative AI with domain expertise to identify “alpha signals” of innovation for the development of impactful therapeutic solutions (InveniAI Announces Launch of AlphaMeld Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery).